BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28926289)

  • 1. The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer.
    Rossi L; Pagani O
    J Womens Health (Larchmt); 2018 Apr; 27(4):466-475. PubMed ID: 28926289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
    Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy for premenopausal women with breast cancer.
    Puhalla S; Brufsky A; Davidson N
    Breast; 2009 Oct; 18 Suppl 3(0 3):S122-30. PubMed ID: 19914530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
    Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
    Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Bao T; Davidson NE
    Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 9. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 12. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Prowell TM; Davidson NE
    Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
    Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
    Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

  • 18. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
    BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian ablation as a treatment for breast cancer.
    Sainsbury R
    Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LHRH-agonist versus chemotherapy in premenopausal breast cancer?
    Klijn JG
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S45-6. PubMed ID: 12409071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.